Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J. Y., Maki, R. G., Schwartz, G. K., Antonescu, C. R., Singer, S., Coindre, J. M., Bui, B. (June 2012) Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol, 23 (6). pp. 1601-7. ISSN 1569-8041 (Electronic)0923-7534 (Linking)
Abstract
BACKGROUND: Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. METHODS: From 2000 to 2010, 208 patients with advanced WDLPS/DDLPS received chemotherapy in 11 participating institutions. Clinical and pathological data were collected by reviewing medical records. RESULTS: Median age was 63 years (range 32-84). Combination chemotherapy was delivered in 85 cases (41%) and single agent in 123 cases (59%), respectively. One hundred and seventy-one patients (82%) received an anthracycline-containing regimen. Using RECIST, objective response was observed in 21 patients (12%), all treated with anthracyclines. Median progression-free survival (PFS) was 4.6 months [95% confidence interval (CI) 3.3-5.9]. On multivariate analysis, age and performance status (PS) were the sole factors significantly associated with poor PFS. Median overall survival (OS) was 15.2 months (95% CI 11.8 -18.7). On multivariate analysis, grade and PS were the sole factors significantly associated with OS. CONCLUSIONS: Chemotherapy was associated with clinical benefit in 46% of patients with advanced WDLPS/DDLPS. OS remains poor, even though visceral metastatic disease is less frequent than in other sarcomas.
| Item Type: | Paper |
|---|---|
| Uncontrolled Keywords: | Adult Aged Aged, 80 and over Anthracyclines/*therapeutic use Antineoplastic Agents/*therapeutic use Disease-Free Survival Female Humans Kaplan-Meier Estimate Liposarcoma/*drug therapy/mortality/secondary Male Middle Aged Multivariate Analysis Neoplasm Grading Prognosis Proportional Hazards Models Retroperitoneal Neoplasms/*drug therapy/mortality/pathology Retrospective Studies Treatment Outcome |
| Subjects: | diseases & disorders > cancer > drugs and therapies > chemotherapy diseases & disorders > cancer > drugs and therapies diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matt Covey |
| Date: | June 2012 |
| Date Deposited: | 20 Oct 2016 16:52 |
| Last Modified: | 20 Oct 2016 16:52 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/33738 |
Actions (login required)
 |
Administrator's edit/view item |